Experimental drug aims to reverse liver scarring in MASH cirrhosis

NCT ID NCT07704892

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether efimosfermin alfa can improve liver fibrosis in adults with compensated cirrhosis caused by MASH (a fatty liver disease). Participants receive either the drug or a placebo via injection. The main goal is to see if liver scarring improves by at least one stage without worsening MASH.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called efimosfermin alfa, given as a subcutaneous injection
What this could lead to: If successful, this could provide a treatment to improve liver fibrosis and prevent progression to liver failure in people with MASH-related cirrhosis.
What could go wrong: This is an early-stage Phase 3 trial with a moderate number of participants; the drug may not show significant benefit over placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease Fibrosis metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.